Trial Profile
Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms SafeDrop
- 24 Apr 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2022 Planned End Date changed from 1 Dec 2022 to 11 Nov 2022.
- 31 Mar 2022 Status changed to active, no longer recruiting.